Name of the Condition
- Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites (ICD-10 Code: C84.68)
Summary
Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites (ALCL, ALK-positive) is a rare subtype of non-Hodgkin lymphoma that primarily affects T-lymphocytes. It is characterized by the presence of the anaplastic lymphoma kinase (ALK) protein, resulting from a specific genetic rearrangement. This condition typically presents as a rapidly growing tumor involving lymph nodes at multiple sites. ALCL, ALK-positive is more common in children and young adults and is generally considered aggressive but responsive to targeted therapies.
Causes
The exact cause of ALK-positive ALCL is not fully understood. The disease is driven by a genetic translocation involving the ALK gene, most commonly the t(2;5)(p23;q35) translocation, which results in overexpression of the ALK protein. This abnormal protein promotes uncontrolled cell growth and survival. While the translocation is a key driver, other genetic mutations may contribute to disease development, though specific environmental triggers remain unclear.
Risk Factors
- Age: More common in children and young adults, with a peak incidence in the second and third decades of life.
- Gender: Slightly higher prevalence in males.
- Genetic factors: Presence of the ALK translocation is a primary risk factor.
- Immunosuppression: Weakened immune systems may increase risk.
Symptoms
Symptoms may include rapidly enlarging, painless lymph node swelling at multiple sites, fever, night sweats, unexplained weight loss, and fatigue. Skin lesions or other soft tissue involvement may also occur. The rapid growth of tumors can lead to localized pressure symptoms depending on the affected areas.
Diagnosis
Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans) to identify lymph node involvement, and biopsy of affected tissue. Histopathological examination confirms the presence of large, anaplastic cells, and immunohistochemistry or molecular testing detects the ALK protein or genetic translocation. Staging helps determine the extent of disease.
Treatment Options
Treatment typically includes systemic chemotherapy, often with regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Targeted therapies, such as ALK inhibitors (e.g., crizotinib), may be used for ALK-positive cases. Radiation therapy can address localized disease, and stem cell transplantation may be considered for relapsed or refractory cases. Treatment plans are tailored to disease stage and patient factors.
Prognosis and Follow-Up
Prognosis varies based on disease stage, response to treatment, and patient age. ALK-positive ALCL generally has a better prognosis than ALK-negative subtypes, with higher response rates to therapy. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term surveillance may be recommended, especially in younger patients.
Complications
Complications can include treatment-related side effects (e.g., infection, organ toxicity), disease progression or relapse, and potential long-term effects of therapy (e.g., secondary malignancies). Advanced disease may lead to organ dysfunction due to tumor burden or treatment resistance.
Lifestyle & Prevention
No specific lifestyle changes prevent ALCL, but maintaining overall health supports treatment tolerance. Avoiding known carcinogens and managing immune health may be beneficial. Patients should follow medical advice, attend regular screenings, and report new symptoms promptly.
When to Seek Professional Help
Seek medical attention for persistent, unexplained lymph node swelling, fever, night sweats, or weight loss. Rapidly enlarging nodes or systemic symptoms warrant prompt evaluation. Follow up with a hematologist-oncologist for diagnosis and management.
Tips for Medical Coders
Code C84.68 is specific to anaplastic large cell lymphoma, ALK-positive, with lymph node involvement at multiple sites. Ensure documentation confirms both the ALK-positive status and multi-site lymph node involvement. Do not use this code for single-site lymph node disease or extra-nodal presentations. Verify that the diagnosis aligns with histopathological and molecular findings to support accurate coding.